Restoring breathing capacity in Duchenne muscular dystrophy by activating the brain
New research published in The Journal of Physiology today suggests that enhancing breathing via the brain may limit deficiencies in respiratory capacity in Duchenne muscular dystrophy (DMD) patients.
Duchenne muscular dystrophy (DMD) is a fatal genetic neuromuscular disease, which can lead to respiratory failure. Respiratory muscle dysfunction is recognized in DMD, however a thorough assessment of nervous system control of respiratory muscles is lacking. .. [read more]
What is Duchenne muscular dystrophy?
Context:
Duchenne muscular dystrophy (DMD) is a severe, progressive genetic disorder characterized by the relentless weakening and wasting of muscles. It is the most common and most severe form of muscular dystrophy, predominantly affecting boys, with an incidence of approximately 1 in 3,500 to 5,000 male births . The condition is caused by mutations in the DMD gene, located on the X chromosome, which is responsible for producing a vital protein called dystrophin . Dystrophin acts as a critical structural anchor within muscle cells, linking the internal cytoskeleton to the extracellular matrix to protect muscle fibers from the mechanical stress of contraction and relaxation . In the absence of functional dystrophin, muscle fibers become fragile and susceptible to damage, leading to a cascade of cellular events including necrosis, inflammation, and the eventual replacement of muscle tissue with fibrotic scar tissue and fat .
The clinical signs of DMD typically emerge in early childhood, often between the ages of 2 and 5, with parents noticing delayed motor milestones such as difficulty walking, running, or climbing stairs . As the disease progresses, affected children may develop a characteristic waddling gait, walk on their toes, and display the Gowers’ sign—a maneuver where they use their hands to “walk” up their legs to stand from a squatting position due to proximal muscle weakness . An early and deceptive sign is calf muscle pseudohypertrophy, where the muscles appear enlarged due to fatty infiltration, despite being weak . While muscle weakness is the primary feature, the absence of certain dystrophin isoforms in the brain also means that some children with DMD may experience learning difficulties, cognitive impairment, or behavioral challenges .
The relentless nature of the disease leads to predictable, life-altering milestones. By around the age of 10 to 12, the majority of patients lose the ability to walk independently and require a wheelchair for mobility . As the condition advances, it affects the respiratory muscles and the heart, leading to significant and life-limiting complications. Cardiomyopathy, a weakening of the heart muscle, and respiratory insufficiency are the most common causes of morbidity and mortality in DMD, with most patients not surviving beyond their third decade of life without intensive management . Furthermore, the progressive muscle weakness predisposes individuals to spinal deformities like scoliosis and painful joint contractures, which can complicate care and impair quality of life .
While there is currently no cure for Duchenne muscular dystrophy, significant advances in multidisciplinary care and symptomatic treatments have improved both life expectancy and quality of life . A cornerstone of management is the use of corticosteroids, which help to reduce inflammation, slow the loss of muscle strength, and delay the onset of scoliosis and the need for ventilation . Alongside this, management requires a coordinated, multidisciplinary team approach that includes physical and occupational therapy to maintain function and range of motion, respiratory support such as non-invasive ventilation, and cardiac care to monitor and treat cardiomyopathy . In recent years, novel genetic therapies have emerged, including exon-skipping drugs designed to produce a shortened but functional dystrophin for specific genetic mutations, and the approval of the first gene therapy (micro-dystrophin), offering hope for directly addressing the root genetic cause of this devastating disease .
